for normal age-related cognitive impairments many studies have reported protective effects of dietary restriction [22] [23] [24] [25] .
Although dietary restriction is remarkably protective in age-related diseases, including in models of neurodegenerative diseases, protocols of dietary restriction are clearly not practical for most humans, and indeed entail unacceptable deleterious effects including distracting hunger and fatigue [26] .
Therefore from a translational perspective the mechanisms mediating protective effects of dietary restriction have been the subject of extensive research [27] . The best understanding of these mechanisms has been obtained in 
creb-binding protein (cbp) mediates neuroprotective effects of dietary restriction
Similarly, we reported that inhibiting Cbp [28] . Similarly mutant huntingtin, which causes Huntington's disease, interferes with Cbp function, which is directly linked to neurotoxicity [29] [30] [31] Cbp is a co-transcriptional activator involved in many processes, and does not bind DNA directly, so it was not clear from these studies 
Neuroprotective effects of pparalpha agonists
The first PPAR isolated was PPAR-alpha, cloned on the basis of its homology with nuclear steroid receptors and its activation by several compounds known to stimulate peroxisome proliferation and reduce lipidemia [48] . These investigators reported that expression of PPARalpha was highest in liver, kidney, and heart, with relatively low expression in the brain [48] . However at least part of the protective effect was due direct dampening of the immune response and may have been independent of PPAR-alpha [61, 62] . Finally, PPAR-alpha agonists protect neurons from toxicity due to nitric oxide (either produced chemically or by activated microglia) [63] .
Neuroprotective effects of ppargamma agonists
The second PPAR discovered in mammals, as homologous to PPAR-alpha, was PPARgamma [64, 65] PPAR-gamma exhibits an expression pattern broadly similar to PPARalpha, including, notably, low but detectable expression in the brain [64] , including in neurons [66] . Like PPAR-alpha, PPAR-gamma is activated by a variety of lipophilic substances Compared with the neuroprotective effects of PPAR-alpha agonists described above, neuroprotective effects of PPAR-gamma agonists have been far more robustly reported, and have been the subject of several recent reviews [68, 69] . For example, many reports have demonstrated that PPAR-gamma agonists used to treat Type 2 diabetes are neuroprotective in animal models of stroke [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] . PPAR-gamma agonists are similarly protective in models of multiple sclerosis [82] , amyotrophic lateral sclerosis [83] , Parkinson's disease [84] , and Alzheimer's disease [85, 86] . Furthermore PPARgamma agonists also protect against diabetic neuropathy [87, 88] . It should be noted that since germline PPAR-gamma knockout mice are not viable, it has not been possible to demonstrate genetically that protective effects of PPARgamma agonists are necessarily mediated by PPAR-gamma.
One early clinical trials suggested that the PPAR-gamma agonist pioglitazone improved cognitive function as well as cerebral blood flow in patients with Alzheimer's disease [89] . However another small study failed to observe improvements in cognitive symptoms in patients with Alzheimer's [90] . While a randomized clinical trial failed to demonstrate efficacy of rosiglitazone to improve symptoms in Alzheimer's disease [91] , larger trials are necessary to clarify the efficacy of pioglitazone to improve cognitive symptoms in Alzheimer's disease [92] .
Neuroprotective effects of ppardelta agonists
The last PPAR discovered in mammals is now referred to as PPAR-delta (or sometimes PPARbeta/delta or PPAR-beta), since the beta form was originally discovered in Xenopus and the delta form is the mammalian homolog [65] . This isoform is expressed more broadly than the other isoforms [65] but is less studied in part because whereas PPAR-alpha and PPAR-gamma are targets of drugs used clinically to treat diabetes (by fibrates and glitazones, respectively), so far there are no clinically approved drugs that target PPAR-delta. PPAR-delta appears to act more like PPAR-alpha than PPAR-gamma, in that it induces genes that promote beta oxidation [93] . PPAR-delta is of particular interest in the context of neurodegeneration because it is the most abundant PPAR in the brain, specifically in neurons and oligodendrocytes, but not astrocytes [94] , again similar to PPAR-alpha.
Despite its relative novelty, several reports have already indicated neuroprotective effects of PPAR-delta in models of Alzheimer's disease [95] , stroke [96, 97] , and Parkinson's disease [96] .
Neuroprotective effects of rxr agonists
As described above, PPAR transcription factors dimerize with RXR transcription factors to activate transcription. It is therefore of particular interest that oral administration of the RXR agonist bexarotene reduces beta plaque area more than 50% within 72 hours of administration and stimulates rapid reversal of cognitive, social, and olfactory deficits in a mouse model of Alzheimer's disease [98] . RXR agonists were similarly protective in mouse models of Parkinson's disease [99] .
Neuroprotective effects of pgc-1-alpha
As discussed above, in addition to Cbp, PPARs also co-recruit the transcriptional co-activator 
conclusions
The mechanisms by which activation of the PPAR transcription complex lead to neuroprotection are not entirely clear but probably involve both metabolic and anti-inflammatory effects [63, 68] . We hypotthesize that the development of better PPAR agonists with improved capacity to cross the blood-brain barrier will lead to dramatic improvements in the treatment of neurodegenerative diseases. [60] Lovett-Racke A.E., Hussain R.Z., Northrop S., Choy J., Rocchini A.,
